Market Overview - The cement sector experienced a decline of 0.67% on November 17, with Ta Pai Group leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Individual Stock Performance - Notable gainers in the cement sector included: - Guotong Co., Ltd. (002205) with a closing price of 16.74, up 9.99% on a trading volume of 163,400 shares and a turnover of 266 million [1] - Huan Zhi Wu Shi (002596) with a closing price of 5.08, up 5.83% on a trading volume of 1,746,900 shares and a turnover of 884 million [1] - Fujian Cement (600802) with a closing price of 8.50, up 3.66% on a trading volume of 886,500 shares and a turnover of 743 million [1] - Conversely, Ta Pai Group (002233) saw a decline of 2.16% with a closing price of 8.62, trading 114,200 shares for a turnover of 98.77 million [2] - Other notable decliners included: - Huaxin Cement (600801) down 2.00% to 22.53 [2] - Conch Cement (600585) down 1.56% to 23.32 [2] Capital Flow Analysis - The cement sector saw a net inflow of 63.15 million from institutional investors, while retail investors experienced a net outflow of 10.57 million [2] - Key stocks with significant capital flow included: - Guotong Co., Ltd. (002205) with a net inflow of 91.54 million from institutional investors, representing 34.38% of its trading volume [3] - Huan Zhi Wu Shi (002596) with a net inflow of 18.09 million from institutional investors, representing 2.05% [3] - Ta Pai Group (002233) had a net outflow of 45.46 million from retail investors, representing -17.07% [3]

Core Viewpoint - The company has received a clinical trial approval notice for its drug JFAN-1001, which is not expected to have a significant impact on its recent operating performance [1][2]. Drug Information - JFAN-1001 mesylate capsules are a new anti-tumor drug developed by the company, classified as a Class 1 chemical drug, indicated for locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR-T790M secondary mutation [2]. - The clinical trial application for JFAN-1001 in combination with crizotinib soft capsules was accepted on September 8, 2025, and is currently undergoing Phase II clinical trials in China [2]. - The drug has also received clinical trial approval from the U.S. Food and Drug Administration [2]. Company Impact - The approval of the clinical trial is not expected to significantly affect the company's recent operating performance [1][2]. - The company acknowledges the uncertainties associated with drug development, including the lengthy and complex process from research to market, which may impact clinical trial progress and results [2].

Core Viewpoint - The company announced that its subsidiary has received approval for a new drug clinical trial from the National Medical Products Administration [1] Group 1 - The full subsidiary involved is Zhejiang Jianfeng Pharmaceutical Co., Ltd. [1] - The holding subsidiary that received the approval is Zhejiang Jianfeng Yien Biotechnology Co., Ltd. [1] - The approved drug is named JFAN-1001 mesylate capsule [1] Group 2 - The approval includes three notification numbers: 2025LP03024, 2025LP03025, and 2025LP03026 [1]

Group 1: China Construction - The total new contracts signed by China Construction from January to October reached 3.61 trillion yuan, representing a year-on-year increase of 1% [1] Group 2: Changyuan Power - Changyuan Power's subsidiary received approval for the 100MW wind power project in Songzi, Hubei [2] Group 3: China Metallurgical Group - China Metallurgical Group reported a total new contract amount of 845.07 billion yuan from January to October, a decrease of 11.8% year-on-year, while overseas contracts increased by 7.3% to 71.16 billion yuan [4] Group 4: Shapuaisi - Shapuaisi received approval for clinical trials of deoxycorticosterone ketone solution, intended for use during cataract surgery [5] Group 5: Jianfeng Group - Jianfeng Group's subsidiary received approval for clinical trials of a new drug for treating advanced non-squamous non-small cell lung cancer [7] Group 6: Chongqing Steel - Chongqing Steel announced the resignation of its president Meng Wenwang due to work adjustments [8] Group 7: Tianma Technology - Tianma Technology reported an output of approximately 1732.99 tons of eel in October, with a total output of about 15218.73 tons from January to October [10] Group 8: Qingyuan Co. - Qingyuan Co.'s controlling shareholder reduced holdings of convertible bonds by 685,400 units, accounting for 13.71% of the total issuance [11] Group 9: Spring Airlines - Spring Airlines reported a passenger turnover of 506,200.49 million kilometers in October, a year-on-year increase of 20.06% [12] Group 10: China Merchants Port - China Merchants Port reported a total container volume of 17.1714 million TEUs from January to October, a year-on-year increase of 5.1% [13] Group 11: Yangdian Technology - Yangdian Technology announced a change in control following a share transfer [15] Group 12: Wanfu Biology - Wanfu Biology decided to postpone the implementation of its Knowledge City production base project [16] Group 13: Iwu Biology - Iwu Biology terminated the research project for a specific drug, which will reduce its 2025 net profit by approximately 333.79 million yuan [17] Group 14: Hainan Rubber - Hainan Rubber received an insurance payout of 22.9241 million yuan due to revenue loss from rubber price fluctuations [19] Group 15: Xinjiang Tianye - Xinjiang Tianye plans to establish a joint venture with Tianchi Energy to develop coal chemical projects [20] Group 16: China Coal Energy - China Coal Energy's executive director and president Zhao Rongzhe resigned due to reaching retirement age [22] Group 17: Huading Co. - Huading Co. received approval for a stock issuance to specific investors from the Shanghai Stock Exchange [24] Group 18: Zhongmu Co. - Zhongmu Co. decided to waive its right of first refusal for a 4.04% stake in a subsidiary [25] Group 19: Tianlong Co. - Tianlong Co. reported that its subsidiary's stock issuance was approved by the Beijing Stock Exchange [26] Group 20: Hualan Co. - Hualan Co.'s subsidiary plans to invest 20 million yuan in a biotechnology company [27] Group 21: Haichen Pharmaceutical - Haichen Pharmaceutical received a drug registration certificate for a new injection [28] Group 22: Aier Eye Hospital - Aier Eye Hospital plans to invest 300 million yuan in wealth management products [29] Group 23: Xiamen Engineering Machinery - Xiamen Engineering Machinery announced a planned share reduction by a major shareholder [30] Group 24: Guotai Group - Guotai Group successfully acquired 100% of a mining technology company for 110.1 million yuan [31] Group 25: Wanfeng Aowei - Wanfeng Aowei reached a settlement regarding an arbitration matter with a subsidiary [32] Group 26: Taihe Technology - Taihe Technology is undergoing technical upgrades for its ethylene carbonate project [33] Group 27: Renhe Pharmaceutical - Renhe Pharmaceutical's controlling shareholder plans to reduce holdings by 0.21% [34] Group 28: Changshu Bank - Changshu Bank's second-largest shareholder increased its stake to 3.98% [35] Group 29: Overseas Chinese Town A - Overseas Chinese Town A reported a 57% decrease in contract sales in October [36] Group 30: Canadian Solar - Canadian Solar's controlling shareholder expects total revenue of 1.3 to 1.5 billion USD in Q4 2025 [38] Group 31: Zhonggong Education - Zhonggong Education's controlling shareholder's shares will be auctioned due to a loan dispute [40] Group 32: Aikexibo - Aikexibo's shareholders plan to reduce their holdings by up to 3% [42] Group 33: Wanhua Chemical - Wanhua Chemical's shareholder plans to reduce holdings by up to 0.5% [44] Group 34: Jujie Microfiber - Jujie Microfiber's controlling shareholder plans to reduce holdings by up to 2% [45] Group 35: Wangsu Technology - Wangsu Technology's shareholder plans to reduce holdings by up to 1% [46] Group 36: Tianli Lithium Energy - Tianli Lithium Energy received a patent for lithium-ion battery materials [47] Group 37: Heshun Electric - Heshun Electric won a 40 million yuan project for energy storage services [49] Group 38: Changchun High-tech - Changchun High-tech's subsidiary received FDA approval for a clinical trial of a new drug [51] Group 39: Dongrui Co. - Dongrui Co. received an additional export quota for live pigs to Hong Kong [52] Group 40: Zhongwei Co. - Zhongwei Co. set the H-share issuance price at 34 HKD per share [53] Group 41: Fospower Technology - Fospower Technology plans to invest in a lithium sulfide project with partners [54]

Market Overview - The cement sector experienced a decline of 0.22% on November 14, with Sichuan Jinding leading the drop [1] - The Shanghai Composite Index closed at 3990.49, down 0.97%, while the Shenzhen Component Index closed at 13216.03, down 1.93% [1] Individual Stock Performance - Notable gainers in the cement sector included: - Hainan Ruize (002596) with a closing price of 4.80, up 5.26% on a trading volume of 1.4978 million shares and a turnover of 721 million yuan [1] - Fujian Cement (600802) closed at 8.20, up 4.19% with a trading volume of 886,600 shares and a turnover of 711 million yuan [1] - Major decliners included: - Sichuan Jinding (600678) which closed at 10.29, down 5.77% with a trading volume of 715,100 shares and a turnover of 748 million yuan [2] - Qingsong Jianhua (600425) closed at 4.84, down 1.43% with a trading volume of 310,500 shares and a turnover of 151 million yuan [2] Capital Flow Analysis - The cement sector saw a net outflow of 194 million yuan from institutional investors, while retail investors contributed a net inflow of 174 million yuan [2] - The capital flow for specific stocks showed: - All Yu Group (601992) had a net inflow of 17.78 million yuan from institutional investors, but a net outflow of 2.87 million yuan from retail investors [3] - Fujian Cement (600802) experienced a net inflow of 12.18 million yuan from institutional investors, but a net outflow of 15.99 million yuan from retail investors [3]

证券代码：600668 证券简称：尖峰集团 编号：临 2025-060 浙江尖峰集团股份有限公司 关于子公司获得药物临床试验批准通知书的公告 通知书编号：2025LP03024、2025LP03025和2025LP03026 申请事项：境内生产药品注册临床试验 申请人：浙江尖峰亦恩生物科技有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 近日，本公司全资子公司浙江尖峰药业有限公司的控股子公司浙江尖峰亦 恩生物科技有限公司（以下简称"尖峰亦恩"），收到国家药品监督管理局核准签 发的《药物临床试验批准通知书》（通知书编号：2025LP03024、2025LP03025和2025L P03026）。现将有关详情公告如下： 一、药品基本信息 药物名称：JFAN-1001 甲磺酸盐胶囊 受理号：CXHL2500971 、CXHL2500972 、CXHL2500973 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 09 月 08 日受理的 JFAN-1001 甲磺酸盐胶囊符合药 ...

Core Viewpoint - The company has received approval for a new anti-tumor drug, JFAN-1001, which targets a specific mutation in lung cancer [1] Group 1: Company Developments - Zhejiang Jianfeng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Jianfeng Group, has received a clinical trial approval notice from the National Medical Products Administration [1] - The approval includes three notification numbers: 2025LP03024, 2025LP03025, and 2025LP03026 [1] Group 2: Product Information - JFAN-1001 mesylate capsules are developed as a new anti-tumor drug by Jianfeng Yien Biotechnology Co., Ltd., a holding subsidiary of Jianfeng [1] - The drug is classified as a Class 1 chemical drug and is indicated for locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR-T790M secondary mutation [1]

Core Viewpoint - The company has received approval for a clinical trial of its new anti-tumor drug, JFAN-1001, which targets advanced non-squamous non-small cell lung cancer patients with specific genetic mutations [1] Group 1: Company Developments - Zhejiang Jianfeng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Jianfeng Group, has received a clinical trial approval notice from the National Medical Products Administration for JFAN-1001 mesylate capsules [1] - The clinical trial will evaluate the combination of JFAN-1001 with Tarceva (erlotinib) soft capsules in patients with advanced non-squamous non-small cell lung cancer [1] - JFAN-1001 is classified as a Class 1 chemical drug and is indicated for locally advanced or metastatic non-small cell lung cancer with EGFR-T790M secondary mutations [1] Group 2: Clinical Trial Status - The clinical trial application for JFAN-1001 was accepted on September 8, 2025, and is currently undergoing Phase II clinical trials in China [1] - The drug has also received clinical trial permission from the U.S. Food and Drug Administration [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for its new anti-tumor drug, JFAN-1001 mesylate capsules, which targets a specific mutation in non-small cell lung cancer [1] Group 1: Company Developments - The wholly-owned subsidiary of the company,尖峰亦恩, has been granted the Clinical Trial Approval Notice for JFAN-1001 mesylate capsules [1] - JFAN-1001 mesylate capsules are classified as a Class 1 chemical drug and are developed for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR-T790M secondary mutation [1]

Core Viewpoint - The company has received approval for a clinical trial of its new anti-tumor drug JFAN-1001, which targets advanced non-squamous non-small cell lung cancer patients with specific genetic mutations [1] Group 1: Company Developments - Zhejiang Jianfeng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Jianfeng Group, has received a clinical trial approval notice from the National Medical Products Administration for JFAN-1001 mesylate capsules [1] - The clinical trial will evaluate the combination of JFAN-1001 with Tarceva (erlotinib) soft capsules in patients with advanced non-squamous non-small cell lung cancer [1] - JFAN-1001 is classified as a Class 1 chemical drug and is indicated for locally advanced or metastatic non-small cell lung cancer with EGFR-T790M secondary mutations [1] Group 2: Clinical Trial Status - The clinical trial application for JFAN-1001 was accepted on September 8, 2025, and is currently undergoing Phase II clinical trials in China [1] - The drug has also received clinical trial permission from the U.S. Food and Drug Administration [1]